ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia

ICER

19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net health benefit compared to standard clinical management.

Given the high costs of standard care, cost effectiveness modelling finds beti-cel meets commonly accepted value thresholds at an anticipated price of $2.1 million — if that price is subject to an 80% payback for treatment failure.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder